This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rizk, N. P. Articles by Rusch, V. W. Search for Related Content PubMed PubMed Citation Articles by Rizk, N. P. Articles by Rusch, V. W. Related Articles Related Correspondence Social Bookmarking                            What's this?

American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal Adenocarcinoma

Nabil P. Rizk, Ennapadam Venkatraman, Manjit S. Bains, Bernard Park, Raja Flores, Laura Tang, David H. Ilson, Bruce D. Minsky, Valerie W. Rusch

From the Thoracic Service, Department of Surgery; Biostatistics Service, Department of Epidemiology and Biostatistics; Pathology Department; Gastrointestinal Oncology Service, Department of Medicine; and the Radiation Oncology Department, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Nabil P. Rizk, MD, Department of Surgery, Thoracic Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Ste C883, New York, NY 10021; e-mail: rizkn{at}mskcc.org

Purpose In patients with adenocarcinoma of the esophagus who receive preoperative chemoradiotherapy (CRT), American Joint Committee on Cancer (AJCC) stage, pathologic complete response (pCR), and estimated treatment response are various means used to stratify patients prognostically after surgery. However, none of these methods has been formally evaluated. The purpose of this study was to establish prognostic pathologic variables after CRT.

Patients and Methods A retrospective review was performed of patients with esophageal adenocarcinoma who received CRT before esophagectomy. Data collected included demographics, CRT details, pathologic findings, and survival. Statistical methods included recursive partitioning and Kaplan-Meier analyses.

Results Two hundred seventy-six patients were appropriate for this analysis. Kaplan-Meier analysis indicates that the current AJCC system poorly distinguishes between stages 0 to IIA (P = .52), IIB to III (P = .87), and IVA to IVB (P = .30). The presence of a pCR conferred improved survival over residual disease (P = .01). Recursive partitioning analysis indicates that involved lymph nodes and metastatic disease are the best predictors of survival and that depth of invasion and degree of treatment response are less predictive.

Conclusion The current AJCC staging system is not a good predictor of survival after CRT. Although patients with a pCR do have improved long-term survival relative to patients with residual disease, this method places too much emphasis on residual depth of invasion and fails to identify patients with residual disease who have good long-term survival. Recursive partitioning analysis more accurately identifies nodal disease and metastatic disease as the most important prognostic variables. Degree of treatment response is less prognostic than nodal involvement.

Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• For Localized Gastroesophageal Cancer, You Give Chemoradiation Before Surgery, but Then What Happens?
  Jaffer A. Ajani, Arlene M. Correa, Stephen G. Swisher, and Tsung-Teh Wu
  JCO 2007 25: 4315-4316 [Full Text]

This article has been cited by other articles:

				D. W. Cescon, P. A. Bradbury, K. Asomaning, J. Hopkins, R. Zhai, W. Zhou, Z. Wang, M. Kulke, L. Su, C. Ma, et al. p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis Clin. Cancer Res., May 1, 2009; 15(9): 3103 - 3109. [Abstract] [Full Text] [PDF]

				M. Stahl, M. K. Walz, M. Stuschke, N. Lehmann, H.-J. Meyer, J. Riera-Knorrenschild, P. Langer, R. Engenhart-Cabillic, M. Bitzer, A. Konigsrainer, et al. Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction J. Clin. Oncol., February 20, 2009; 27(6): 851 - 856. [Abstract] [Full Text] [PDF]

				J. M. Donahue, F. C. Nichols, Z. Li, D. A. Schomas, M. S. Allen, S. D. Cassivi, A. Jatoi, R. C. Miller, D. A. Wigle, K. R. Shen, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann. Thorac. Surg., February 1, 2009; 87(2): 392 - 398. [Abstract] [Full Text] [PDF]

				S. K. Thompson, A. R. Ruszkiewicz, G. G. Jamieson, A. Esterman, D. I. Watson, B. P. L. Wijnhoven, P. J. Lamb, and P. G. Devitt Improving the Accuracy of TNM Staging in Esophageal Cancer: A Pathological Review of Resected Specimens Ann. Surg. Oncol., December 1, 2008; 15(12): 3447 - 3458. [Abstract] [Full Text] [PDF]

				A. P. Barbour, M. Jones, M. Gonen, D. C. Gotley, J. Thomas, D. B. Thomson, B. Burmeister, and B. M. Smithers Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response Ann. Surg. Oncol., October 1, 2008; 15(10): 2894 - 2902. [Abstract] [Full Text] [PDF]

				M. Tachibana, S. Kinugasa, N. Hirahara, and H. Yoshimura Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 427 - 431. [Abstract] [Full Text] [PDF]

				J. A. Ajani, A. M. Correa, S. G. Swisher, and T.-T. Wu For Localized Gastroesophageal Cancer, You Give Chemoradiation Before Surgery, but Then What Happens? J. Clin. Oncol., September 20, 2007; 25(27): 4315 - 4316. [Full Text] [PDF]